Summary

Marksans Pharma Ltd has reported the financial results for the quarter and half-year ended on September 30, 2025. The company has reported a record quarterly revenue of X720 Cr, a 12.2% YoY increase. The EBITDA stood at Rs. 144.5 cr., with a margin of 20.1%. The PAT grew 70% quarter-on-quarter. The US region recorded solid growth, demonstrating resilience amid macro challenges. The UK market also witnessed improved demand. The company remains optimistic about sustaining this momentum into the second half of the year.

Key Highlights

1. 1

   Operating revenue stood at Rs. 720.4 cr., up by 12.2% YoY

2. 2

   Gross profit stood at Rs. 411.8 cr., up by 7.4% YoY

3. 3

   EBITDA stood at Rs. 144.5 cr., with a margin of 20.1%

4. 4

   EPS was at Rs. 2.2

5. 5

   US & North America Formulation business reported revenues of Rs. 387.3 cr. in Q2FY26

6. 6

   Revenues from the UK & Europe Formulation business in Q2FY26 stood at Rs. 245.3 cr.

7. 7

   Australia and New Zealand businesses reported revenues of Rs. 61.3 cr. in Q2FY26

8. 8

   RoW business reported revenues of Rs. 26.5 cr. in Q2FY26

9. 9

   Cash generated from operations at X 75.2 cr during H1FY26

10. 10

    Capex of X73.2 cr incurred during H1FY26

11. 11

    Working capital cycle ~150 days for Q2FY26

12. 12

    Research & development (R&D) spends at X 26.2 cr in H1FY26, 2.0% of consolidated revenue